{"id":"placebo-upadacitinib","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Upper respiratory tract infection"},{"rate":"8-12","effect":"Headache"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-8","effect":"Nausea"},{"rate":"10-15","effect":"Increased cholesterol"},{"rate":"2-4","effect":"Herpes zoster reactivation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Upadacitinib selectively inhibits JAK1, a key enzyme in the JAK-STAT signaling pathway that mediates inflammatory cytokine signaling. By blocking JAK1, it reduces the production of pro-inflammatory cytokines and chemokines, thereby suppressing immune-mediated inflammation. This mechanism makes it effective for treating autoimmune and inflammatory conditions.","oneSentence":"Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:33.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Atopic dermatitis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT07492251","phase":"PHASE2","title":"Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2026-06-01","conditions":"Lichen Penis Planus","enrollment":56},{"nctId":"NCT05843643","phase":"PHASE3","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-07-19","conditions":"Systemic Lupus Erythematosus","enrollment":1000},{"nctId":"NCT05889182","phase":"PHASE3","title":"A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-06-21","conditions":"Hidradenitis Suppurativa","enrollment":1328},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT04169373","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-26","conditions":"Spondyloarthritis","enrollment":734},{"nctId":"NCT06701331","phase":"PHASE3","title":"Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-12-22","conditions":"Atopic Dermatitis","enrollment":99},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT04161898","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-02-04","conditions":"Takayasu Arteritis (TAK)","enrollment":56},{"nctId":"NCT06012240","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-10-11","conditions":"Alopecia Areata","enrollment":1500},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT03006068","phase":"PHASE3","title":"A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2017-01-31","conditions":"Ulcerative Colitis (UC)","enrollment":950},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT07023302","phase":"PHASE3","title":"A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-19","conditions":"Alopecia Areata","enrollment":123},{"nctId":"NCT03568318","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-09","conditions":"Atopic Dermatitis","enrollment":1533},{"nctId":"NCT03607422","phase":"PHASE3","title":"A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-27","conditions":"Atopic Dermatitis","enrollment":912},{"nctId":"NCT06118411","phase":"PHASE3","title":"A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-12-19","conditions":"Vitiligo","enrollment":614},{"nctId":"NCT06928272","phase":"PHASE3","title":"Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study","status":"RECRUITING","sponsor":"Douglas D. Fraser","startDate":"2025-09-10","conditions":"Long COVID","enrollment":348},{"nctId":"NCT03569293","phase":"PHASE3","title":"Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-08-13","conditions":"Atopic Dermatitis","enrollment":912},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT03104374","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-01","conditions":"Psoriatic Arthritis","enrollment":642},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03345823","phase":"PHASE3","title":"A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-03-21","conditions":"Crohn's Disease","enrollment":747},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06227910","phase":"PHASE3","title":"A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-01-02","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT06454188","phase":"PHASE4","title":"A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"CARE ARTHRITIS LTD.","startDate":"2024-11-06","conditions":"Psoriatic Arthritis, Spondyloarthritis, Axial","enrollment":100},{"nctId":"NCT04451772","phase":"PHASE2","title":"A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-27","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":185},{"nctId":"NCT04927975","phase":"PHASE2","title":"Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-06-30","conditions":"Non-Segmental Vitiligo","enrollment":185},{"nctId":"NCT06390722","phase":"PHASE3","title":"A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2024-05-23","conditions":"Atopic Dermatitis, Sleep Disturbance","enrollment":""},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT03738397","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-02-21","conditions":"Atopic Dermatitis","enrollment":673},{"nctId":"NCT02706951","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-23","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02365649","phase":"PHASE2","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-03-17","conditions":"Crohn's Disease","enrollment":220},{"nctId":"NCT03978520","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-07-25","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":341},{"nctId":"NCT02706873","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis","enrollment":1002},{"nctId":"NCT02720523","phase":"PHASE2, PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-22","conditions":"Rheumatoid Arthritis","enrollment":197},{"nctId":"NCT02675426","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-17","conditions":"Rheumatoid Arthritis","enrollment":661},{"nctId":"NCT03178487","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-24","conditions":"Ankylosing Spondylitis (AS)","enrollment":187},{"nctId":"NCT03661138","phase":"PHASE3","title":"A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-27","conditions":"Atopic Dermatitis","enrollment":272},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT04430855","phase":"PHASE2","title":"A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-14","conditions":"Hidradenitis Suppurativa (HS)","enrollment":68},{"nctId":"NCT03345849","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-07","conditions":"Crohn's Disease","enrollment":526},{"nctId":"NCT03345836","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-29","conditions":"Crohn's Disease","enrollment":624},{"nctId":"NCT02819635","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-09-26","conditions":"Ulcerative Colitis (UC)","enrollment":1302},{"nctId":"NCT03653026","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-12-06","conditions":"Ulcerative Colitis (UC)","enrollment":522},{"nctId":"NCT02955212","phase":"PHASE3","title":"A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-01-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":338},{"nctId":"NCT03823378","phase":"PHASE2","title":"A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-05-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":97},{"nctId":"NCT01960855","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT02066389","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-26","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT03682705","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-10-08","conditions":"Rheumatoid Arthritis (RA)","enrollment":242},{"nctId":"NCT04666675","phase":"PHASE3","title":"A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2020-12-24","conditions":"Atopic Dermatitis (AD)","enrollment":""},{"nctId":"NCT02925117","phase":"PHASE2","title":"A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-10-25","conditions":"Atopic Dermatitis","enrollment":167},{"nctId":"NCT01741493","phase":"PHASE1","title":"A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-11","conditions":"Rheumatoid Arthritis","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rinvoq","Placebo"],"phase":"marketed","status":"active","brandName":"Placebo Upadacitinib","genericName":"Placebo Upadacitinib","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1. Used for Rheumatoid arthritis, Atopic dermatitis, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}